Kimia Biosciences [KIMIABL] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison
Kimia Biosciences
BSE
Loading...
Divi's Laboratories
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Kimia Biosciences wins in 3 metrics, Divi's Laboratories wins in 9 metrics, with 0 ties. Divi's Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Kimia Biosciences | Divi's Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | 67.57 | N/A |
| Price-to-Book Ratio | 16.79 | 10.40 | Divi's Laboratories |
| Debt-to-Equity Ratio | 394.92 | 0.03 | Divi's Laboratories |
| PEG Ratio | N/A | 2.55 | N/A |
| EV/EBITDA | 10.94 | 49.66 | Kimia Biosciences |
| Profit Margin (TTM) | 7.31% | 23.89% | Divi's Laboratories |
| Operating Margin (TTM) | 6.75% | 25.60% | Divi's Laboratories |
| EBITDA Margin (TTM) | 6.75% | 25.60% | Divi's Laboratories |
| Return on Equity | N/A | 14.64% | N/A |
| Return on Assets (TTM) | N/A | 12.94% | N/A |
| Free Cash Flow (TTM) | N/A | $2.15B | N/A |
| Dividend Yield | N/A | 0.91% | N/A |
| 1-Year Return | -26.03% | -5.14% | Divi's Laboratories |
| Price-to-Sales Ratio (TTM) | 1.39 | 16.13 | Kimia Biosciences |
| Enterprise Value | $2.06B | $1,522.01B | Divi's Laboratories |
| EV/Revenue Ratio | 1.72 | 15.77 | Kimia Biosciences |
| Gross Profit Margin (TTM) | N/A | 60.33% | N/A |
| Revenue per Share (TTM) | $26 | $363 | Divi's Laboratories |
| Earnings per Share (Diluted) | N/A | $86.82 | N/A |
| Beta (Stock Volatility) | 0.97 | 0.18 | Divi's Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Kimia Biosciences vs Divi's Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Kimia Biosciences | 1.05% | -0.96% | 1.90% | -46.26% | -6.31% | -17.56% |
| Divi's Laboratories | 4.77% | 2.26% | -3.33% | -15.42% | 10.79% | -4.06% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Kimia Biosciences | -26.03% | -18.52% | 17.43% | 84.95% | 84.95% | 84.95% |
| Divi's Laboratories | -5.14% | 63.08% | 80.80% | 444.71% | 1,530.25% | 8,023.95% |
News Based Sentiment: Kimia Biosciences vs Divi's Laboratories
Kimia Biosciences
News based Sentiment: NEGATIVE
Kimia Biosciences experienced a significant decline in stock price and financial performance during the month of October 2025. The substantial drops in net sales and profit, combined with a high debt-to-equity ratio, create a concerning picture for investors. The closure of the trading window and AGM proceedings are standard corporate governance but don't offset the negative financial trends.
Divi's Laboratories
News based Sentiment: MIXED
Divi's Laboratories reported strong quarterly results and is strategically diversifying its revenue base, but faces operational challenges and mixed analyst sentiment. The technical indicators also present a cautious outlook, creating a complex investment narrative with both opportunities and risks.
Performance & Financial Health Analysis: Kimia Biosciences vs Divi's Laboratories
| Metric | KIMIABL | DIVISLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.75B | ₹1.61T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 5,546 | 455,187 |
| 90 Day Avg. Volume | 12,368 | 395,686 |
| Last Close | ₹37.38 | ₹6,104.50 |
| 52 Week Range | ₹34.25 - ₹86.85 | ₹4,955.00 - ₹7,071.50 |
| % from 52W High | -56.96% | -13.67% |
| All-Time High | ₹86.85 (Jul 02, 2025) | ₹7,071.50 (Jul 08, 2025) |
| % from All-Time High | -56.96% | -13.67% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.14% |
| Quarterly Earnings Growth | -0.58% | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.24% |
| Operating Margin (TTM) | 0.07% | 0.26% |
| Return on Equity (TTM) | N/A | 0.15% |
| Debt to Equity (MRQ) | 394.92 | 0.03 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹2.11 | ₹563.87 |
| Cash per Share (MRQ) | ₹0.04 | ₹132.86 |
| Operating Cash Flow (TTM) | ₹0 | ₹19.67B |
| Levered Free Cash Flow (TTM) | ₹0 | ₹21.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.91% |
| Last 12-Month Dividend | N/A | ₹60.00 |
Valuation & Enterprise Metrics Analysis: Kimia Biosciences vs Divi's Laboratories
| Metric | KIMIABL | DIVISLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 67.57 |
| Forward P/E | N/A | 104.19 |
| PEG Ratio | N/A | 2.55 |
| Price to Sales (TTM) | 1.39 | 16.13 |
| Price to Book (MRQ) | 16.79 | 10.40 |
| Market Capitalization | ||
| Market Capitalization | ₹1.75B | ₹1.61T |
| Enterprise Value | ₹2.06B | ₹1.52T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.72 | 15.77 |
| Enterprise to EBITDA | 10.94 | 49.66 |
| Risk & Other Metrics | ||
| Beta | 0.97 | 0.18 |
| Book Value per Share (MRQ) | ₹2.11 | ₹563.87 |
Financial Statements Comparison: Kimia Biosciences vs Divi's Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | KIMIABL | DIVISLAB |
|---|---|---|
| Revenue/Sales | N/A | ₹24.10B |
| Cost of Goods Sold | N/A | ₹9.56B |
| Gross Profit | N/A | ₹14.54B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | N/A | ₹6.17B |
| EBITDA | N/A | ₹8.48B |
| Pre-Tax Income | N/A | ₹7.33B |
| Income Tax | N/A | ₹1.88B |
| Net Income (Profit) | N/A | ₹5.45B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | KIMIABL | DIVISLAB |
|---|---|---|
| Cash & Equivalents | N/A | ₹4.15B |
| Total Current Assets | N/A | ₹100.81B |
| Total Current Liabilities | N/A | ₹14.52B |
| Long-Term Debt | N/A | ₹20.00M |
| Total Shareholders Equity | N/A | ₹149.69B |
| Retained Earnings | N/A | ₹134.00B |
| Property, Plant & Equipment | N/A | ₹3.19B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | KIMIABL | DIVISLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | KIMIABL | DIVISLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 5,546 | 455,187 |
| Average Daily Volume (90 Day) | 12,368 | 395,686 |
| Shares Outstanding | 47.31M | 265.47M |
| Float Shares | 3.80M | 120.77M |
| % Held by Insiders | 0.92% | 0.52% |
| % Held by Institutions | 0.00% | 0.29% |
Dividend Analysis & Yield Comparison: Kimia Biosciences vs Divi's Laboratories
| Metric | KIMIABL | DIVISLAB |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹60.00 |
| Last 12-Month Dividend Yield | N/A | 0.91% |
| 3-Year Avg Annual Dividend | N/A | ₹50.00 |
| 3-Year Avg Dividend Yield | N/A | 0.70% |
| 3-Year Total Dividends | N/A | ₹150.00 |
| Ex-Dividend Date | N/A | Jul 25, 2025 |